ReviewNutrition & metabolism2026
Sarcopenic obesity in cirrhosis: prognostic value and future perspectives.
Review in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Sarcopenic obesity (Sa-O) is an emerging prognostic factor in patients with cirrhosis, yet its diagnostic criteria and clinical significance remain incompletely defined. This narrative review synthesizes evidence from the past five years on the pathogenesis, diagnostic criteria, and prognostic implications of Sa-O in cirrhosis. Diagnostic criteria were categorized according to their definitions of sarcopenia and obesity, and the clinical utility of assessment tools was evaluated. Prognostic value was examined across seven clinical domains. Existing evidence indicates that Sa-O is associated with increased mortality and adverse post-transplant outcomes. Limited data suggest potential links with classic cirrhosis complications, while cardiovascular events remain underexplored as primary endpoints. Current studies on acute-on-chronic liver failure focus on sarcopenia or obesity in isolation rather than their coexistence. Health-related quality of life and the integration of Sa-O into established prognostic score models are rarely addressed. In summary, Sa-O should be recognized as a key prognostic factor in cirrhosis and represents a modifiable target for early lifestyle intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.